corresp
     
 
  Robyn Zolman
November 30, 2010
  Direct: 303.298.5740
 
  Fax: 303.313.2830
 
  RZolman@gibsondunn.com

 
  Client: C 12412-00001
VIA EDGAR
Ms. Rose Zukin
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re:   BioCryst Pharmaceuticals, Inc.
Form 10-K for the year ended December 31, 2009
Filed March 9, 2010
Definitive Proxy Statement on Schedule 14A
Filed April 6, 2010
File No. 000-23186
Dear Ms. Zukin:
On behalf of BioCryst Pharmaceuticals, Inc. (the “Company”) this letter confirms that as discussed with you today, the Company will respond to the Staff’s November 16, 2010 letter to the Company on or before December 15, 2010.
Sincerely,
/s/ Robyn Zolman
Robyn Zolman
REZ/rez
cc:   Alane Barnes, BioCryst Pharmaceuticals, Inc.
Brian Lane, Gibson, Dunn & Crutcher LLP